Mehri S. Mckellar
Experienced in Lymphangitis

Dr. Mehri S. Mckellar

Infectious Disease
40 Duke Medicine Cir, 
Durham, NC 
On Staff At
Offers Telehealth
25 Years of Experience
Experienced in Lymphangitis
40 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

I am an infectious diseases physician with a focus on persons who have HIV. One of my major clinical and research interests is HIV prevention, such as rapid HIV testing and prevention through pre-exposure prophylaxis or PrEP in which people can take one pill per day to prevent HIV. I serve as the Medical Director of the Duke PrEP Clinic and have a number of projects in the community involving PrEP, including with populations who are difficult to reach. I am originally from Arizona, and love to hike, ski, and spend time with my family and friends.

Dr. Mckellar is rated as an Experienced provider by MediFind in the treatment of Lymphangitis. Her top areas of expertise are HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex.

Her clinical research consists of co-authoring 47 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Arizona College Of Medicine, 2000
Specialties
Infectious Disease
Licenses
Internal Medicine in CA
Board Certifications
American Board Of Internal Med, Infectious Diseases
Fellowships
Infectious Diseases, University of Utah Medical Center
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Duke Infectious Diseases Clinic - Clinic 1K
40 Duke Medicine Cir, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults
A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Biological
Study Drug: GSK3810109A
Study Phase: Phase 2
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
Providing A Resource: Telemedicine at Needle Exchanges to Reach Under-served Populations - Greensboro
Providing A Resource: Telemedicine at Needle Exchanges to Reach Under-served Populations - Greensboro
Enrollment Status: Completed
Publish Date: April 27, 2023
Intervention Type: Drug
Study Drugs: Suboxone, Truvada, Mavyret
Study Phase: Not Applicable
IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect
IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect
Enrollment Status: Completed
Publish Date: November 22, 2021
Intervention Type: Drug
Study Phase: Not Applicable
View 4 Less Clinical Trials

47 Total Publications

Preexposure Prophylaxis to Prevent HIV Acquisition: Perceptions among Sexual and Gender Minority Individuals in North Carolina.
Preexposure Prophylaxis to Prevent HIV Acquisition: Perceptions among Sexual and Gender Minority Individuals in North Carolina.
Journal: Southern medical journal
Published: July 15, 2025
Similar Doctors
Advanced in Lymphangitis
Dr. Octavio Cieza
Infectious Disease
Advanced in Lymphangitis
Dr. Octavio Cieza
Infectious Disease

Unc Physicians Network LLC

507 N Brightleaf Blvd, Suite 201, 
Smithfield, NC 
 (48.0 miles away)
919-934-8544
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Octavio Cieza is an Infectious Disease provider in Smithfield, North Carolina. Dr. Cieza is rated as an Advanced provider by MediFind in the treatment of Lymphangitis. His top areas of expertise are Osteomyelitis, Osteomyelitis in Children, Lymphangitis, and Cellulitis. Dr. Cieza is currently accepting new patients.

Experienced in Lymphangitis
Dr. Jisha S. John
Infectious Disease
Experienced in Lymphangitis
Dr. Jisha S. John
Infectious Disease

Wakemed Specialists Group LLC

2304 Wesvill Ct, 
Raleigh, NC 
 (19.0 miles away)
919-571-1567
Languages Spoken:
English, Hindi, Malayalam
See accepted insurances
Accepting New Patients
Offers Telehealth

Jisha John is an Infectious Disease provider in Raleigh, North Carolina. Dr. John is rated as an Experienced provider by MediFind in the treatment of Lymphangitis. Her top areas of expertise are Osteomyelitis, Osteomyelitis in Children, Lymphangitis, and Infective Endocarditis. Dr. John is currently accepting new patients.

Experienced in Lymphangitis
Dr. Nikolaos Mavrogiorgos
Infectious Disease
Experienced in Lymphangitis
Dr. Nikolaos Mavrogiorgos
Infectious Disease

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.6 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nikolaos Mavrogiorgos is an Infectious Disease provider in Chapel Hill, North Carolina. Dr. Mavrogiorgos is rated as an Advanced provider by MediFind in the treatment of Lymphangitis. His top areas of expertise are Osteomyelitis, Osteomyelitis in Children, Pneumonia, and Myelitis. Dr. Mavrogiorgos is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mckellar's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile